Antibacterial and antiviral medicinal composition and application thereof

An anti-virus and composition technology, applied in the field of medicine, can solve the problems of limited immune validity, low toxicity and side effects, high morbidity, mortality, etc., and achieve the effect of good therapeutic effect

Active Publication Date: 2020-08-07
YUNNAN BAIYAO GROUP
View PDF1 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are more than 10 known viruses that can cause acute respiratory infections. These viruses are generally easy to spread through air droplets. If they are not properly prevented and controlled, they may cause high morbidity and mortality.
Although vaccines can be used clinically to prevent respiratory virus infections, they are only effective against influenza viruses, and the effect is not ideal for other respiratory viruses, and the duration of immunity is relatively limited
In terms of treatment, so far, no chemical drug has been found to have low toxic and side effects while ensuring good curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibacterial and antiviral medicinal composition and application thereof
  • Antibacterial and antiviral medicinal composition and application thereof
  • Antibacterial and antiviral medicinal composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] An antibacterial and antiviral medicinal composition, the raw materials of which include 885g of patchouli, 1869g of herb, 1064g of fennel, 2174g of mugwort leaves, 46g of cloves, 532g of mint, and 10g of natural borneol.

[0081] Use above-mentioned medicinal composition to prepare medicinal volatile oil, preparation method is as follows:

[0082] Patchouli herb decoction pieces were crushed through a 20-mesh sieve, soaked overnight in 6 times the weight of water, extracted by steam distillation for 6 hours, and the volatile oil of patchouli was collected, with an extraction rate of 2.26%.

[0083] Atractylodes atractylodis crude powder was taken, soaked in 6 times the weight of water for 0.5h, extracted by steam distillation for 5h, and the volatile oil of atractylodis was collected, with an extraction rate of 1.07%.

[0084] Take the herb medicinal material, soak it in 6 times the weight of water for 2 hours, extract it by steam distillation for 3 hours, and collect ...

Embodiment 2

[0090] An antibacterial and antiviral medicinal composition, the raw materials of which include 663.5g of patchouli, 1402g of herb, 798g of fennel, 1630.5g of mugwort leaves, 32g of cloves, 106.5g of mint, and 2.5g of natural borneol.

[0091] Use above-mentioned medicinal composition to prepare the method for medicinal volatile oil, preparation method is as follows:

[0092] All raw materials are first crushed into coarse powder, after mixing, put in HA220-40-48 supercritical carbon dioxide extraction device, feed liquid carbon dioxide to extract volatile oil, extraction pressure is 28-30Mpa, extraction temperature is 55°C, separation temperature is 45°C, extraction time is 3h , to obtain 106.5 g of extract (total volatile oil), add natural borneol, and heat appropriately (not higher than 60° C.) to completely dissolve the natural borneol to obtain medicinal volatile oil.

Embodiment 1

[0094] Carry out drug efficacy research test to embodiment 1 medicinal volatile oil:

[0095] The doses of mice in the pharmacodynamic study were 65mg / kg, 130mg / kg and 260mg / kg, respectively.

[0096] The doses of guinea pigs in the drug efficacy study were 32mg / kg, 64mg / kg and 128mg / kg respectively.

[0097] The rat doses in the pharmacodynamic study were 37mg / kg, 74mg / kg and 148mg / kg

[0098] 1 Cough induced by concentrated ammonia water in mice (antitussive effect)

[0099] 1.1 Experimental method

[0100] ICR mice, half male and half female. According to weight stratification, they were randomly divided into 6 groups, 14 in each group, respectively: normal control group, model control group, pentoxyverine citrate 20mg / kg group, medicinal volatile oil low dose (65mg / kg) group, In the middle dose of medicinal volatile oil (130mg / kg) group and the high dose of medicinal volatile oil (260mg / kg) group, the mice were intragastrically administered at 20mL / kg (using soybean oi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses an antibacterial and antiviral medicinal composition. The medicinal composition is prepared from the following raw materials in parts by weight: 4 to 14 parts of herba pogostemonis, 9 to 28 parts of rhizoma atractylodis, 5 to 18 parts of herba elsholtziae, 11 to 33 parts of folium artemisiae argyi, 0.1 to 3 parts of flos caryophylli and 2 to 10 parts of herba menthae. The medicinal composition disclosed by the invention can be used for preparing medicines for resisting bacteria and viruses, clearing heat and reducing fever and / or treating respiratory system diseases, and comprises medicines for relieving cough, reducing sputum and treating allergic rhinitis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and more specifically relates to an antibacterial and antiviral medicinal composition and its application. Background technique [0002] Respiratory system diseases are common clinical diseases and frequently-occurring diseases, which are common in microbial infections, including bacteria, viruses, fungi, etc.; they have the characteristics of high incidence, great harm, easy recurrence, and increasing drug resistance. [0003] Among them, bacterial infection is a common cause of respiratory diseases. There are many pathogenic bacteria that cause respiratory bacterial infections, among which Pseudomonas aeruginosa, Staphylococcus aureus, and Klebsiella pneumoniae are more common. Clinically, chronic lung diseases include chronic obstructive pulmonary disease, bronchial asthma, tuberculosis, etc. Once combined with these bacterial infections, it will lead to rapid deterioration of the condition a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/61A61P11/00A61P11/02A61P11/06A61P11/10A61P11/14A61P29/00A61P31/04A61P31/12A61P31/14A61P37/08A61K31/045
CPCA61K36/532A61K36/284A61K36/53A61K36/282A61K36/61A61K36/534A61K31/045A61P31/04A61P31/12A61P31/14A61P29/00A61P11/00A61P11/02A61P11/06A61P11/10A61P11/14A61P37/08A61K2236/331A61K2236/37A61K2300/00Y02A50/30A61K36/36A61K9/4858A61K9/0043A61K9/06A61K47/26A61K47/14A61K47/44A61K47/38A61K9/0073A61K9/008A61K9/0056A61K9/2068A61K9/2031A61P31/00
Inventor 林瑞超董汛崔涛王京昆孙敏
Owner YUNNAN BAIYAO GROUP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap